Elastic NV vs ImmunityBio Inc. Common Stock — how do they compare? Elastic NV trades at $95.26 (market cap $9.77B), while ImmunityBio Inc. Common Stock trades at $10 (market cap $10.33B). The key difference: Elastic NV and ImmunityBio Inc. Common Stock are close in size by market cap, and Elastic NV is more actively traded (945,514 versus 11,745,198). Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| ESTC | IBRX | |
|---|---|---|
Market Cap | $9.77B | $10.33B |
Volume | 945,514 | 11,745,198 |
Sector | Technology | Health |
52-Week High | $99.91 | $11.55 |
52-Week Low | $43.30 | $1.98 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | $8.91B | $10.79B |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.1, down 1.59% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust revenue growth, improving profitability into 2026, and positive sentiment from analysts, with 22 buy ratings and no sells. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in its observability and search platforms.
The stock presents a growth opportunity driven by product innovation and expanding profit margins, but risks include high valuation multiples and competitive pressures in the enterprise software sector. Analyst consensus targets $79.50, below the current price, suggesting cautious optimism amid execution risks and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →